With Promising Results, AstraZeneca Targets Mutated Lung Cancer And Rival … – TheStreet.com

by lowes1 on September 30, 2013

With Promising Results, AstraZeneca Targets Mutated Lung Cancer And Rival
TheStreet.com
AMSTERDAM (TheStreet) — With promising early-stage study results presented this weekend, AstraZeneca's (AZN) experimental lung cancer drug AZD9291 looks to be a potent tumor-shrinking competitor for Clovis Oncology's (CLVS) CO-1686.

and more »

View full post on lung cancer – Google News

Leave a Comment

Previous post:

Next post: